Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1
The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1
REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.
Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.
Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.
Medline introduces Namic Ready Set Kits
In the fast-paced healthcare industry, there is constant pressure to efficiently deliver...
How healthcare providers prevent infection
The spread of infection in the healthcare sector is an ongoing challenge for operators, so what...
There's more to decontamination than just disinfection…
Disinfection is often the main focus in medical device reprocessing, but is only one step of the...
